Cross John Harry III 4

4 · Sonnet BioTherapeutics Holdings, Inc. · Filed Dec 22, 2022

Insider Transaction Report

Form 4
Period: 2022-12-14
Cross John Harry III
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2022-12-14+15,519160,684 total
Footnotes (2)
  • [F1]On December 14, 2022, the Reporting Person was granted 15,519 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024.
  • [F2]Includes unvested RSUs.

Documents

1 file
  • 4
    ownership.xmlPrimary